Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).

ABSTRACT:

Background

Noninvasive biomarkers are needed to guide metastatic castration-resistant prostate cancer (mCRPC) treatment.

Objective

To clinically qualify baseline and on-treatment cell-free DNA (cfDNA) concentrations as biomarkers of patient outcome following taxane chemotherapy.

Design, setting, and participants

Blood for cfDNA analyses was prospectively collected from 571 mCRPC patients participating in two phase III clinical trials, FIRSTANA (NCT01308567) and PROSELICA (NCT01308580). Patients received docetaxel (75mg/m²) or cabazitaxel (20 or 25mg/m²) as first-line chemotherapy (FIRSTANA), and cabazitaxel (20 or 25mg/m²) as second-line chemotherapy (PROSELICA).

Outcome measurements and statistical analysis

Associations between

SUBMITTER: Mehra N 

PROVIDER: S-EPMC6090941 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature